Ownership and insider activity for Keros Therapeutics, Inc. (KROS): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options.
Price
| Price | $10.74 |
| Market Cap | $344M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $23.3M | $7.0M | $265.9M | $230.0M | $279.0M | $331.1M | $559.9M | $287.4M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | $922000 | $216000 | $18.2M | $841000 | $1.1M | $4.5M | $6.4M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $25.5M | $8.9M | $267.7M | $251.4M | $285.8M | $347.3M | $588.9M | $315.4M |
| Property, Plant & Equipment | $1.4M | $1.9M | $1.6M | $2.4M | $17.6M | $19.5M | $23.5M | $21.1M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $27.4M | $11.0M | $269.4M | $255.3M | $306.8M | $370.0M | $615.9M | $338.0M |
| Accounts Payable | $501000 | $2.1M | $2.1M | $3.6M | $3.3M | $5.5M | $4.6M | $2.0M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $11.5M | $4.5M | $7.2M | $11.8M | $16.5M | $24.4M | $27.4M | $20.4M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $14.7M | $10.5M | $7.7M | $12.1M | $29.4M | $37.8M | $44.3M | $34.9M |
| Retained Earnings | -$7.3M | -$19.6M | -$65.0M | -$123.8M | -$228.4M | -$381.4M | -$568.8M | -$481.8M |
| Total Equity | $12.8M | $495000 | $261.7M | $243.2M | $277.4M | $332.2M | $571.6M | $303.1M |
| Total Debt | $788000 | $1.3M | $899000 | $1.1M | $13.3M | $14.4M | $18.9M | $16.9M |
| Net Debt | -$22.5M | -$5.7M | -$265.0M | -$228.9M | -$265.8M | -$316.7M | -$541.1M | -$270.5M |
| Working Capital | $14.1M | $4.4M | $260.5M | $239.6M | $269.2M | $322.9M | $561.4M | $295.0M |
Financial Health
| Debt / Equity | 0.06 |
| Current Ratio | 21.96 |
Profitability
| Return on Equity | -21.40% |
| Return on Invested Capital | -35.25% |
| Return on Assets | -28.91% |
| Gross Margin | 94.68% |
| Operating Margin | -675.82% |
| Net Margin | -553.88% |
Related companies: ABSI · CRVS · CTMX · MLTX · NAGE · OLMA · RGNX
Explore sector: Healthcare · Biotechnology
More sections of KROS: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks